Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Towa Files Additional Request for Livalo Patent Invalidity in December 2020
Towa Pharmaceutical filed an additional request in December 2020 with the Japan Patent Office seeking to invalidate a patent associated with Kowa’s hypercholesterolemia treatment Livalo OD Tablets (pitavastatin), it revealed on April 14. Regarding the Livalo generic, Kowa on March…
To read the full story
Related Article
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Kowa Appeals to Intellectual Property High Court in Livalo Damage Suit
April 8, 2022
- Towa Wins Livalo Damage Suit; Kowa to Appeal Ruling
March 25, 2022
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
- Kowa Sues Towa Again over Livalo Generics, Seeking Over 4.8 Billion Yen in Additional Damages for FY2017
April 7, 2020
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Kowa Sues Towa for Damages Caused by Livalo Generics
June 25, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…